ArticleTherapeutics and clinical risk management2026
Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United Kingdom.
Article in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.Drugs - real world outcomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide, is approved in Germany and the United Kingdom (UK) for patients experiencing migraine ≥4 days per month, and it is reimbursed for patients where ≥4-5 (Germany) or ≥3 (UK) prior migraine preventive treatments have failed. We evaluated real-world clinical effectiveness and healthcare resource utilization (HCRU) in patients initiating fremanezumab in Germany and the UK. Methods: This non-interventional, retrospective, physician panel-based, online, multicenter chart review study included adult patients with chronic migraine (CM) or episodic migraine (EM) with first fremanezumab treatment initiation (index date) from June 2019 or later (Germany), and from June 2020 or later (UK). Changes in monthly migraine days (MMD), monthly headache days (MHD), and disability outcomes (Migraine Disability Assessment [MIDAS] and Headache Impact Test-6 [HIT-6]) were evaluated from baseline (pre-index) to 3 months post-index, and changes in HCRU were evaluated from 6 months pre-index to 6 months post-index. Results: The study population included 207 German and 183 UK patients (CM, 48.3% and 95.1%; monthly dosing, 59.4% and 51.9%, respectively). Reductions in MMD and MHD were observed in the German cohort (percent reductions: 60.2% and 55.1%, respectively) and the UK cohort (51.9% and 47.3%, respectively; all Conclusion: Fremanezumab demonstrated real-world clinical effectiveness in German and UK cohorts and may decrease the burden of migraine for patients and providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.